

To view this email as a web page, go [here](#).



## INNOVATION AND COMMERCIALIZATION

# OHSU Innovates

June 2, 2021

## FEATURED NEWS

### OHSU startup company receives investment and support



OHSU startup [Inherent Targeting](#) has been named to the first cohort of the [Sci-Founder](#) fellowship program. The program provides a cash investment of \$400,000, along with mentorship and a peer-network of other scientists starting companies. Inherent Targeting is developing fluorescent dyes to guide surgeries and improve clinical outcomes. The company was founded by Connor Barth, Ph.D. '18, OHSU, [Summer Gibbs, Ph.D.](#), associate professor of biomedical engineering, OHSU, and Lei Wang, postdoctoral scholar, [Gibbs laboratory](#), OHSU.

---

### A big win for a Portland biotech startup



Portland biotech startup [Sparrow Pharmaceuticals](#), founded by OHSU entrepreneur-in-residence [David Katz](#), secured \$50 million Series A Financing. [Read more.](#)

---

**Capsigen, Inc, enters strategic research collaboration with Biogen, Inc.**



On May 10, 2021, OHSU startup [Capsigen, Inc.](#), [announced](#) that it has entered into a strategic research collaboration with Biogen, Inc., to discover and develop novel adeno-associated virus (AAV) capsids that may facilitate the development of new gene therapies for CNS and neuromuscular disorders. Capsigen's proprietary TRADE™ platform and associated technologies may have applicability across Biogen's gene therapy pipeline. TRADE™ was invented by [Hiroyuki Nakai, M.D., Ph.D.](#), OHSU School of Medicine Distinguished Professor of Molecular Medicine, Molecular and Medical Genetics, School of Medicine.

TECHNOLOGIES AVAILABLE FOR LICENSING

**OHSU #2907** - Small molecule activates innate immune responses controlled by the human protein STING

**OHSU #2850** - Bioactive polymers with anti-fouling properties for medical implants

**OHSU #2685** - IV ultrasound machine

**OHSU #2833** - secreTRAP: a system for monitoring and quantifying protein secretion from single cells

NEWLY LICENSED OR OPTIONED OHSU TECHNOLOGIES

**OHSU # 1238** - Compounds having antiparasitic or anti-infectious activity (Inventors [Aaron Nilsen, Ph.D.](#), and [Michael Riscoe, Ph.D.](#))

**OHSU # 1771** - Materials from the BioLibrary

**OHSU # 1946** - Carbonate and ester prodrugs of 3-diaryletherquinolones and other substituted 4-oxo-linked quinolones (Inventors [Aaron Nilsen, Ph.D.](#), and [Michael Riscoe, Ph.D.](#))

**OHSU # 2200** - Blood volume determination via intravenous optical fiber technology (Inventors [Theodore Hobbs, D.V.M., M.C.R.](#), & Ravi Samatham, Ph.D.)

**OHSU # 2703** - Airflow limiting or fully restricting device (ALFRD) (Inventor [Kimberly Hutchinson, M.D.](#))

**OHSU # 2853** - A fine-tuned oxazine-based fluorophore library for in vivo nerve-specific imaging (Inventors Connor Barth, Ph.D., [Summer Gibbs, Ph.D.](#), and Lei Wang, Ph.D.)

**OHSU # 2914** - Novel routes to the synthesis of Endochin-Like Quinolones (ELQ) (Inventors [Stone Doggett, M.D.](#), [Aaron Nilsen, Ph.D.](#), and [Michael Riscoe, Ph.D.](#))

**OHSU # 2975** - Streamlined, late-stage, cyclization chemical synthesis of Endochin-Like Quinolones (Inventors [Aaron Nilsen, Ph.D.](#), and [Michael Riscoe, Ph.D.](#))

**OHSU # 3005** - A sensitive, low cost viral infection detection chemistry (Inventors [Marcel Curlin, M.D.](#), and [Joe Gray, Ph.D.](#))

**OHSU # 3022** - Orally bioavailable CREB inhibitors for the treatment of cancer (Inventors Bingbing Li, M.D., Ph.D., [Mark Miller, D.M.D.](#), and [Xiangshu Xiao, Ph.D.](#))

**Patent # 11,009,394** - Multispectrum super resolution microscopy

**Patent # 11,000,546** - Immunomodulatory properties of MAPCs and uses thereof

**Patent # 10,995,121** - Human cytomegalovirus comprising exogenous antigens

#### RESEARCHERS IN NEW INDUSTRY-FUNDED RESEARCH PROJECTS

**Jeffrey Gold, M.D., and Matthias Merkel, M.D., Ph.D.** - Mission Control usability analysis

**Scott Hansen, Ph.D.** - COVID19 long hauler study

**Guang Fan, M.D., Ph.D., and Donna Hansel, M.D., Ph.D.** - Test for COVID-19

**Richard Maziarz, M.D.** - OHSU developmental studies for treatment of patients with intractable seizures

**Andrew Kaempf, M.S., and Byung Park, Ph.D.,** - Non-interventional retrospective data analysis of health records of the treatment patterns of newly diagnosed AML patients

#### UPCOMING EVENTS

JUNE 7-18	<a href="#">2021 I-Corps Bio-Entrepreneurship Workshop</a>
JUNE 8	<a href="#">OCTRI Design Studio for Career Development Awards</a>
JUNE 9	<i>OBI Lunch and Learn</i> <a href="#">Retaining + Recruiting Top Talent in a Post-COVID World</a>

JUNE 10-11 and  
14-18

BIO Digital

JUNE 14

*Technology Association of Oregon*  
Intro to Oregon Startup Community


JUNE 22

*OCTRI Research Forum*  
Sex and Gender Considerations in Clinical  
Research

#### SPONSORS

We welcome and appreciate the collaborative nature of organizations that want to be a part of the ongoing innovative and entrepreneurial efforts at OHSU. Thank you to our sponsors!

GOLD



SILVER



BRONZE



Klarquist

Questions? Contact us at [techmgmt@ohsu.edu](mailto:techmgmt@ohsu.edu).

This monthly publication is created in collaboration with OHSU Technology Transfer, OHSU Collaborations and Entrepreneurship, and the Oregon Clinical and Translational Research Institute.

3181 S.W. Sam Jackson Park Rd. Portland, OR, 97239, US

[Unsubscribe](#)